Autoinflammatory & rare systemic diseases
Achievement and Usefulness of Intermediate Treatment Targets for Still Disease Proposed by the European Alliance of Associations for Rheumatology and the Paediatric Rheumatology European Society
Authors' conclusion
The EULAR/PReS intermediate treatment targets for Still disease are useful in the clinical management of AOSD.
Study context
- Population
- Consecutive patients with adult-onset Still disease (AOSD) (Yamaguchi criteria) at Keio University Hospital, April 2012–May 202447 (75.8%) female
- Participants
- 62 patients
- Outcome
- Achievement rates of EULAR/Paediatric Rheumatology European Society (PReS) intermediate treatment targets at day 7, week 4, month 3 and month 6
Methodological detailssingle-centre, consecutive patients
- Single-centre
- Consecutive patients
Main finding
As reported in the abstract
Achievement of recommended treatment targets
Day 7 target achieved
67.2%
Week 4 target achieved
61.1%
Month 3 target achieved
3.3%
Month 6 target achieved
1.7%
Observational data: associations, not effects.
Further findings
| Outcome | HR for recurrence (95% CI) | |
|---|---|---|
| Recurrence after month 6, by CID at month 6 · median observational period of 7.1 yearsCID at month 6vs No CID at month 6 | 0.27 (0.11–0.68) | |
| 0.10.31310HR for recurrence (log scale) |
Successful GC withdrawal, by CID at month 3 and biologic use at month 6
| HR for successful GC withdrawal (95% CI) | ||
|---|---|---|
| CID at month 3 | 2.51 (1.15–5.46) | |
| Biologic agents at month 6 | 2.29 (1.14–4.61) | |
| 0.20.5125HR for successful GC withdrawal (log scale) |
Recurrence after month 6, by CID at month 6 · median observational period of 7.1 years
- Patients who achieved CID at month 6 had fewer recurrences thereafter
Original publication
Achievement and Usefulness of Intermediate Treatment Targets for Still Disease Proposed by the European Alliance of Associations for Rheumatology and the Paediatric Rheumatology European Society. J Rheumatol. Published 1 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →